Revolution Medicines (RVMD) is back in focus after the U.S. Food and Drug Administration issued a “safe to proceed” letter for expanded access to its investigational pancreatic cancer therapy, daraxonrasib, for eligible U.S. patients.

The FDA’s expanded access decision comes after a busy period for Revolution Medicines, with the stock’s 30-day share price return of 10.01% and 90-day share price return of 54.05% pointing to strong momentum. The very large 1-year and 3-year total shareholder returns indicate that early investors have already seen substantial gains.

If you are looking for more cancer and biotech related opportunities in this space, it could be worth scanning 33 healthcare AI stocks as a starting point.

With Revolution Medicines posting a larger quarterly loss yet trading at about a 21% discount to analyst targets and an implied large intrinsic discount, investors may ask whether there is still a buying opportunity or if the market is already pricing in future growth.

Most Popular Narrative: 12.1% Overvalued

With Revolution Medicines last closing at $149.94 against a narrative fair value of $133.70, the current price sits above what this widely followed framework implies.

The move toward targeted oncology treatments for high unmet need tumors such as pancreatic, lung and colorectal cancer aligns with the company’s RAS(ON) portfolio, which could influence long term revenue growth if multiple registrational programs convert to approved therapies.

Want to see the full playbook behind that premium price tag? The narrative leans on ambitious revenue ramps, margin shifts and a punchy future earnings multiple. Curious which assumptions really carry the weight here?

Result: Fair Value of $133.70 (OVERVALUED)

However, the story could shift quickly if the capital intensive RAS focused pipeline hits trial setbacks, or if heavy 2026 operating expenses strain that US$2.03b cash pile.

Another Angle: DCF Points The Other Way

While the consensus narrative flags Revolution Medicines as about 12.1% overvalued versus its $133.70 fair value estimate, the SWS DCF model tells a very different story, suggesting the stock is trading around 70.2% below an indicated fair value of $502.47. When two frameworks disagree this sharply, which set of assumptions are you more comfortable leaning on?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Revolution Medicines for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment clearly split between upbeat potential and real execution risks, it makes sense to move fast, review the evidence, and weigh both sides using 2 key rewards and 2 important warning signs

Looking for more investment ideas?

Do not stop at a single stock when there are entire groups of opportunities waiting to be tested against your goals, risk comfort, and time horizon.

• Target potential mispricings by scanning 46 high quality undervalued stocks that combine solid fundamentals with room for the market to reassess their worth.
• Prioritise resilience by checking 68 resilient stocks with low risk scores if you want stocks with steadier risk profiles to balance out bolder positions.
• Stay early to potential stories by reviewing the screener containing 23 high quality undiscovered gems before they appear on everyone else’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.